[New trends in the prevention of myointimal hyperplasia and anastomotic fibroplasia].
Vascular reconstructive surgery has faced, since the beginning, with a complex biologic phenomenon, jeopardizing the results, which is the miointimal hyperplasia and anastomotic fibroplasia, developed at the vascular anastomosis or following balloon angioplasty, leading often to a vessel occlusion and failure of the revascularization procedure. Multiple and diversified research projects have been dedicated, along the years, to the study of the intimal mechanisms and attempts to control the phenomenon by pharmacotherapeutic agents, but the results are still far of being regarded as satisfactory. The author makes a review on the pathogenesis of the miointimal hyperplasia and anastomotic fibroplasia and proceeds to a critical analysis on the most recently introduced innovations, such as is the case of the drug eluting stents, the brachitherapy and the molecular and genetic therapies.